Exploratory Phase 2 Results of Combination Oral Therapy for Alzheimer’s Justify Further Study

Exploratory Phase 2 Results of Combination Oral Therapy for Alzheimer’s Justify Further Study
Pharnext  is reporting positive Phase 2 results from its investigative pleodrug PXT-864, a new oral combination of existing therapies, for the treatment of Alzheimer’s disease. Results from the exploratory study were presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) meeting, held recently in San Diego. PLEODIAL-I (NCT02361424) was a Phase 2, 12-week preliminary efficacy study of several doses of PXT-864 (a

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *